Cerebrolysin vs Leucine Enkephalin (Leu-Enkephalin)
A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Cerebrolysin
Cerebrolysin is a brain-derived peptide mixture produced by controlled enzymatic breakdown of porcine brain proteins. Unlike synthetic peptides, it is a complex of ~25% low-molecular-weight neuropeptides and ~75% free amino acids, with the bioactive peptide fraction mimicking the endogenous neurotrophic factors BDNF, NGF, GDNF, and CNTF in their mechanisms. It has a 30+ year clinical history in Eastern Europe and Asia for stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia — with a substantial human trial database.
Full profileLeucine Enkephalin (Leu-Enkephalin)
One of the two primary endogenous enkephalins, alongside met-enkephalin. This pentapeptide (Tyr-Gly-Gly-Phe-Leu) acts primarily on δ-opioid receptors and secondarily on μ-opioid receptors. Research interests span pain modulation, neuroprotection, mood regulation, and immune system modulation. Extremely short half-life in vivo due to rapid enkephalinase degradation.
Full profile| Cerebrolysin | Leucine Enkephalin (Leu-Enkephalin) | |
|---|---|---|
| Category | Nootropic & Cognitive | Nootropic & Cognitive |
| Also known as | FPF 1070, EBEWE Cerebrolysin, Brain-derived peptide mixture | Leu5-enkephalin, YGGFL, L-enkephalin, endogenous opioid pentapeptide |
| Evidence | Research-stage | Research-stage |
| Dosing range | 5mL–30mL mL, Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access | 0.1mg–1mg mg, Intranasal or SC; extremely short half-life requires frequent dosing or continuous delivery |
| Administration | Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min), Intramuscular injection (research use — lower bioavailability), Subcutaneous injection (less common) | Intranasal, Subcutaneous injection, Intraventricular (research only) |
| Key side effects | Injection site pain (IM route), Hyperthermia / fever (rare, higher doses), Agitation or anxiety (uncommon), Nausea | Tolerance development with repeated use (opioid receptor class effect), Mild euphoria (δ-opioid mediated), Nausea (at high doses), Constipation (opioid class effect at high doses) |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: Cerebrolysin — Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min), Intramuscular injection (research use — lower bioavailability), Subcutaneous injection (less common); Leucine Enkephalin (Leu-Enkephalin) — Intranasal, Subcutaneous injection, Intraventricular (research only).
- Dosing units differ: Cerebrolysin is dosed in mL, Leucine Enkephalin (Leu-Enkephalin) in mg — they operate at different scales.
- Frequency: Cerebrolysin is typically Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access; Leucine Enkephalin (Leu-Enkephalin) is Intranasal or SC; extremely short half-life requires frequent dosing or continuous delivery.
- Research depth: this profile cites 3 sources for Cerebrolysin vs 2 for Leucine Enkephalin (Leu-Enkephalin).
How each works
Cerebrolysin
Cerebrolysin's neuroprotective effects have been demonstrated in over 100 clinical trials, though most are from Eastern European and Asian centers with varying methodological quality. The CACTUS trial (N=256, multicenter) showed significant improvement in cognitive outcomes after ischemic stroke vs placebo. The ARTIST trials evaluated Cerebrolysin for Alzheimer's disease with mixed results. Meta-analyses of stroke and dementia trials generally support modest-to-moderate benefit. Mechanistically, the peptide fraction upregulates BDNF/NGF signaling, reduces excitotoxicity, inhibits caspase-3, and promotes synaptogenesis in animal and in vitro models.
Leucine Enkephalin (Leu-Enkephalin)
Leu-enkephalin was one of the first endogenous opioid peptides characterized, following the discovery of opioid receptors in 1973. It preferentially activates δ-opioid receptors (DOR) over μ-opioid receptors (MOR), producing analgesia, modulation of GABA release, and reward pathway activation. Enkephalinase (neprilysin/NEP, CD10) cleaves the Gly-Phe bond within ~2 minutes IV, necessitating stable analogues or NEP inhibitors for research applications.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.